CN101784533B - 4-苄基氨基喹啉、含有它们的药物组合物和它们在治疗中的用途 - Google Patents

4-苄基氨基喹啉、含有它们的药物组合物和它们在治疗中的用途 Download PDF

Info

Publication number
CN101784533B
CN101784533B CN2008801039514A CN200880103951A CN101784533B CN 101784533 B CN101784533 B CN 101784533B CN 2008801039514 A CN2008801039514 A CN 2008801039514A CN 200880103951 A CN200880103951 A CN 200880103951A CN 101784533 B CN101784533 B CN 101784533B
Authority
CN
China
Prior art keywords
alkyl
methyl
amino
aryl
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008801039514A
Other languages
English (en)
Chinese (zh)
Other versions
CN101784533A (zh
Inventor
W·阿姆伯格
M·奥克斯
W·布拉杰
B·贝尔
W·霍恩伯格
M·梅兹勒
C·W·赫琴斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Deutschland GmbH and Co KG
Original Assignee
Abbott GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott GmbH and Co KG filed Critical Abbott GmbH and Co KG
Publication of CN101784533A publication Critical patent/CN101784533A/zh
Application granted granted Critical
Publication of CN101784533B publication Critical patent/CN101784533B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
CN2008801039514A 2007-08-22 2008-08-22 4-苄基氨基喹啉、含有它们的药物组合物和它们在治疗中的用途 Expired - Fee Related CN101784533B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96572407P 2007-08-22 2007-08-22
US60/965724 2007-08-22
PCT/EP2008/061007 WO2009024611A2 (en) 2007-08-22 2008-08-22 4-benzylaminoquinolines, pharmaceutical compositions containing them and their use

Publications (2)

Publication Number Publication Date
CN101784533A CN101784533A (zh) 2010-07-21
CN101784533B true CN101784533B (zh) 2013-08-21

Family

ID=40378743

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801039514A Expired - Fee Related CN101784533B (zh) 2007-08-22 2008-08-22 4-苄基氨基喹啉、含有它们的药物组合物和它们在治疗中的用途

Country Status (7)

Country Link
US (1) US8420670B2 (cg-RX-API-DMAC10.html)
EP (1) EP2178842A2 (cg-RX-API-DMAC10.html)
JP (1) JP5619609B2 (cg-RX-API-DMAC10.html)
CN (1) CN101784533B (cg-RX-API-DMAC10.html)
CA (1) CA2691450A1 (cg-RX-API-DMAC10.html)
MX (1) MX2009014235A (cg-RX-API-DMAC10.html)
WO (1) WO2009024611A2 (cg-RX-API-DMAC10.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2271625B1 (en) 2008-04-01 2012-09-12 Abbott GmbH & Co. KG Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
WO2011070177A2 (en) * 2009-12-11 2011-06-16 Baltic Technology Development, Ltd. Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
MX2014001457A (es) 2011-08-05 2014-08-21 Abbvie Deutschland Derivados de aminocromano, de aminotiocromano y de amino-1,2,3,4-tetrahidroquinolina composiciones farmaceuticas que los contienen, y su uso en terapia.
WO2013072520A1 (en) 2011-11-18 2013-05-23 AbbVie Deutschland GmbH & Co. KG N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
CA2924689A1 (en) 2013-10-17 2015-04-23 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
JP2016533375A (ja) 2013-10-17 2016-10-27 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー アミノテトラリン誘導体およびアミノインダン誘導体、これらを含有する医薬組成物、および治療におけるこれらの使用
US20200347038A1 (en) 2014-08-29 2020-11-05 Russell Dahl Quinolines that modulate serca and their use for treating disease
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
US20190112317A1 (en) 2015-10-05 2019-04-18 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
CN106749184B (zh) * 2016-11-15 2020-07-17 中山大学 8-氨基喹啉-羟基咔唑杂联体，其制备方法及其药物组合物
CN107337641B (zh) * 2017-07-01 2020-04-28 广东医科大学 一种4-柔性胺基-2-芳乙烯基喹啉类衍生物及其制备方法和应用
US20200275661A1 (en) * 2017-09-26 2020-09-03 Nippon Soda Co., Ltd. Quinoline compound, and agricultural and horticultural fungicide
CA3186668A1 (en) * 2020-07-20 2022-01-27 Neurodon Corporation Quinolines that modulate serca and their use for treating disease
US11730729B2 (en) 2020-07-20 2023-08-22 Neurodon Corporation Quinolines that modulate SERCA and their use for treating disease
TW202320766A (zh) * 2021-09-29 2023-06-01 大陸商上海海和藥物研究開發股份有限公司 一類具有吡啶并六員環結構的ｓｏｓ１抑制劑

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0258755A1 (en) * 1986-08-25 1988-03-09 Hoechst-Roussel Pharmaceuticals Incorporated Alpha-alkyl-4-amino-3-quinoline-methanols and 1-(4-aralkylamino-3-quinolinyl) alkanones, a process for their preparation and their use as medicaments

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2011086A1 (en) * 1989-03-17 1990-09-17 Karl-Heinz Geiss 2-alkyl-4-arylmethylaminoquinolines, the use thereof and drugs prepared therefrom
DE3917232A1 (de) * 1989-05-26 1990-11-29 Basf Ag 4-arylmethamino-2,3-dialkyl-chinoline, ihre verwendung und daraus hergestellte arzneimittel
JPH05213884A (ja) * 1991-06-14 1993-08-24 Upjohn Co:The 新規な４−アミノキノリン類およびこれを有効成分とする高血圧・鬱血性心不全の予防・治療剤
DK0977737T3 (da) * 1997-04-22 2004-01-26 Janssen Pharmaceutica Nv CRF-antagonistisk quino- og quinazoline
US6426364B1 (en) * 1999-11-01 2002-07-30 Nps Allelix Corp. Diaryl-enynes
JP4850332B2 (ja) * 2000-10-18 2012-01-11 東京エレクトロン株式会社 デュアルダマシン構造のエッチング方法
ATE305917T1 (de) 2001-08-16 2005-10-15 Pfizer Prod Inc Difluormethylen aromatische ether und ihre verwendung als inhibitoren des glycin-typ-1- transporters
DE10149370A1 (de) 2001-10-06 2003-04-10 Merck Patent Gmbh Pyrazolderivate
EP1458689B1 (en) 2001-12-20 2007-04-11 H. Lundbeck A/S Aryloxyphenyl and arylsulfanylphenyl derivatives
GB0130696D0 (en) * 2001-12-21 2002-02-06 Smithkline Beecham Plc Chemical Compounds
DE10210779A1 (de) * 2002-03-12 2003-10-09 Merck Patent Gmbh Cyclische Amide
DE10217006A1 (de) 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
FR2838739B1 (fr) 2002-04-19 2004-05-28 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl)benzamide, leur preparation et leur application en therapeutique
FR2842804B1 (fr) 2002-07-29 2004-09-03 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2842805A1 (fr) 2002-07-29 2004-01-30 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide,leur preparation et leur application et therapeutique
US20040152741A1 (en) 2002-09-09 2004-08-05 Nps Allelix Corporation Arylglycine derivatives and their use as glycine transport inhibitors
PT1594840E (pt) 2003-02-17 2007-01-31 Hoffmann La Roche Derivados de piperidina-benzenossulfonamida
JP2006524642A (ja) 2003-04-30 2006-11-02 ハー・ルンドベック・アクチエゼルスカベット 芳香族オキシフェニルおよび芳香族スルファニルフェニル誘導体
GB0314478D0 (en) 2003-06-20 2003-07-23 Glaxo Group Ltd Compounds
GB0314479D0 (en) 2003-06-20 2003-07-23 Glaxo Group Ltd Compounds
GB0314476D0 (en) 2003-06-20 2003-07-23 Glaxo Group Ltd Compounds
NZ544820A (en) * 2003-08-11 2009-02-28 Hoffmann La Roche Piperazine with or-substituted phenyl group and their use as GlyT1 inhibitors
CN100522171C (zh) * 2003-09-09 2009-08-05 弗·哈夫曼-拉罗切有限公司 作为甘氨酸摄取抑制剂、用于治疗精神病的1-苯甲酰基哌嗪衍生物
EP1663232B1 (en) * 2003-09-09 2007-10-03 F. Hoffmann-La Roche Ag 1-(2-amino-benzoyl)-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
FR2861070B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[phenyl(pyrrolidin-2-yl)methyl]benzamide et n-[(azepan-2-yl)phenylmethyl]benzamide, leur preparation et leur application en therapeutique
FR2861073B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861076B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-heterocyclymethylbenzamide, leur preparation et leur application en therapeutique
FR2861074B1 (fr) 2003-10-17 2006-04-07 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861071B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[phenyl(alkylpiperidin-2-yl) methyl]benzamide, leur prepartation et leur application en therapeutique
RU2006117368A (ru) 2003-10-23 2007-12-10 Ф.Хоффманн-Ля Рош Аг (Ch) Производные триазаспиропипередина, предназначенные для применения в качестве ингибиторов glyt-1 при лечении неврологических и психоневрологических нарушений
CA2544981A1 (en) 2003-11-12 2005-05-26 Merck & Co., Inc. 4-phenyl piperidine sulfonyl glycine transporter inhibitors
GB0326840D0 (en) 2003-11-18 2003-12-24 Glaxo Group Ltd Compounds
WO2005058885A2 (en) 2003-12-18 2005-06-30 Glaxo Group Limited Piperidine derivatives and their use as glycine transporter inhibitors
WO2005058317A1 (en) 2003-12-18 2005-06-30 Glaxo Group Limited Glycine transporter-1 inhibirors
GB0329362D0 (en) 2003-12-18 2004-01-21 Glaxo Group Ltd Compounds
US20060074105A1 (en) * 2004-09-20 2006-04-06 Serenex, Inc. Substituted quinoline and quinazoline inhibitors of quinone reductase 2
US20060153963A1 (en) * 2004-11-17 2006-07-13 Ocean Spray Cranberries, Inc. Squeezable fruit sauce and process for making same
US20090221624A1 (en) 2005-05-06 2009-09-03 Olivo Paul D 4-aminoquinoline compounds for treating virus-related conditions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0258755A1 (en) * 1986-08-25 1988-03-09 Hoechst-Roussel Pharmaceuticals Incorporated Alpha-alkyl-4-amino-3-quinoline-methanols and 1-(4-aralkylamino-3-quinolinyl) alkanones, a process for their preparation and their use as medicaments

Also Published As

Publication number Publication date
WO2009024611A2 (en) 2009-02-26
JP5619609B2 (ja) 2014-11-05
CN101784533A (zh) 2010-07-21
US8420670B2 (en) 2013-04-16
CA2691450A1 (en) 2009-02-26
MX2009014235A (es) 2010-04-27
JP2010536829A (ja) 2010-12-02
WO2009024611A3 (en) 2009-09-24
EP2178842A2 (en) 2010-04-28
US20100222346A1 (en) 2010-09-02

Similar Documents

Publication Publication Date Title
US12116351B2 (en) P2X4 receptor antagonist
CN102083797B (zh) 四氢异喹啉、含有它们的药物组合物和它们在治疗中的用途
CN103189337A (zh) 氨基二氢化茚衍生物、包含所述氨基二氢化茚衍生物的药物组合物及其在治疗中的用途
US20040242589A1 (en) 3-arylsulfonyl-7-piperzinyl-indoles-benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
JP2006519258A (ja) ピリジン、ピリミジン、キノリン、キナゾリンおよびナフタレン系のウロテンシン−ｉｉ受容体拮抗薬
TW201043606A (en) N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
EA010265B1 (ru) Производные пиримидина для использования в качестве лигандов ваниллоидных рецепторов и их применение для терапии боли
CN103709097A (zh) 1,3-取代脲或硫脲化合物、其制备方法、药物组合物和应用
JP5290293B2 (ja) ５−ｈｔ７受容体拮抗薬としての置換ピペラジニルピラジンおよびピリジン
CN101171238B (zh) 对5-ht受体具有活性的(3,4-二氢-喹唑啉-2-基)-(2-芳氧基-乙基)胺
JP2002525373A (ja) ２−ピペラジノアルキルアミノベンゾアゾール誘導体：ドーパミン受容体サブタイプ特殊リガンド
JP2004524295A (ja) ウロテンシン−ｉｉ受容体アンタゴニスト
BG108531A (bg) Нови х...'...роарилни производни, 'яхно'о пол"-аван... и използван...
NZ527163A (en) Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
US6031097A (en) 1-(N-(arylalkylaminoalkyl) aminoisoquinolines; a new class of dopamine receptor subtype specific ligands
US5656632A (en) 1-(N'-(arylalkylaminoalkyl)) aminoisoindoles; dopamine receptor subtype specific ligands
CN107118209B (zh) 吡啶骈[3,4-b]吲哚脲类化合物及其作为IDO抑制剂的用途
WO2000012500A2 (en) 2-aryl-4-(1-[4-heteroaryl]piperazin-1-yl) methylimidazoles: dopamine d4 receptor subtype ligands
HK1203191B (en) P2x4 receptor antagonist
WO2015108136A1 (ja) α－置換グリシンアミド誘導体
AU2004233571A1 (en) Imidazolin-2-ylaminophenyl amides as IP antagonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: ABBVIE GERMANY GMBH + CO. KG

Free format text: FORMER OWNER: ABERT GMBH + CO. KG

Effective date: 20130913

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20130913

Address after: Wiesbaden

Patentee after: ABBVIE Deutschland GmbH & Co. KG

Address before: Wiesbaden

Patentee before: Abert GmbH & Co. KG

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130821

Termination date: 20150822

EXPY Termination of patent right or utility model